Risk Mitigation in Sample Storage
Pharmaceutical samples are highly sensitive, requiring precise environmental conditions, such as controlled temperatures, to remain viable. Any deviation can lead to loss of sample integrity, jeopardizing entire research projects. Ali Ismail emphasizes that risk mitigation begins with implementing stringent protocols, including continuous monitoring systems, redundant power supplies, and backup storage facilities, to ensure that no sample is compromised due to unforeseen incidents.
However, the critical question remains: who bears the financial loss if an accident occurs on-site? This is a significant concern for pharmaceutical companies since biological samples, especially patient-derived materials, can be irreplaceable. In most cases, insurance policies and legal agreements with storage facilities outline responsibilities. However, reputational damage and delays in drug development often fall on the pharmaceutical company, affecting both the company and the patients relying on these drugs.
The Impact of Lost Samples on Drug Development
Delayed drug development due to lost samples is not just a financial burden—it can also have dire consequences for patients, particularly those in clinical trials for life-saving treatments. If a company loses critical samples in pre-clinical or clinical stages, it may need to restart parts of the trial, wasting months or even years of progress. The COVID-19 pandemic highlighted this vulnerability as pharmaceutical companies faced unprecedented challenges in keeping supply chains intact while adhering to compliance standards.
Ismail raises another important point: Do we actually know how many samples are lost each year? The industry lacks comprehensive, publicly available data on this, partly because many companies hesitate to disclose such losses due to confidentiality and reputational risks. However, even rare incidents can have massive consequences.
Risk Management and Compliance
To prevent these costly and damaging outcomes, companies like Birka BioStorage invest heavily in risk management strategies. Birka employs advanced monitoring technologies, and their facilities adhere to cGMP (current Good Manufacturing Practice) standards, ensuring the highest level of compliance. In cases of accidents, Birka’s multilayered systems, including automatic failovers and emergency protocols, aim to prevent significant damage.
During the COVID-19 pandemic, when logistical challenges and increased demand for sample storage stressed the system, companies with comprehensive risk management frameworks were better positioned to adapt. Birka’s robust backup strategies ensured they could handle the increased demand without compromising on quality or safety. According to Ismail, consistent compliance is maintained through ongoing audits, staff training, and adherence to strict regulatory guidelines, ensuring that pharmaceutical clients can trust them with their most valuable assets.
Outsourcing as a Strategic Advantage
Given the complexity and high stakes involved in sample storage, Ismail argues that outsourcing storage to specialists like Birka BioStorage offers significant advantages for pharmaceutical companies. Storing sensitive biological materials in-house can be costly and resource-intensive, requiring companies to invest in specialized facilities, ongoing maintenance, and compliance with strict regulations. This diverts attention and resources away from their core focus—drug development.
By outsourcing to a trusted partner like Birka BioStorage, companies can not only mitigate the risks associated with sample storage but also save time and resources. In addition, regulatory bodies benefit from this model, as they do not need to audit warehouses around the world. Instead, they can conduct their audits at one centralized, compliant storage facility, simplifying the regulatory process for all stakeholders involved.
Birka BioStorage as a Partner in Drug Development
Ismail emphasizes that Birka BioStorage is not just a storage provider but an active partner in the drug development process. Their expertise in handling biological materials and maintaining consistent compliance allows pharmaceutical companies to focus on innovation while knowing their samples are in safe hands. This partnership model, which extends beyond mere logistics, helps companies accelerate their research and bring treatments to market faster—an invaluable benefit, especially in the post-COVID-19 landscape where time is of the essence.
In summary, risk mitigation in sample storage is more critical than ever. With increasing complexities in drug development and heightened regulatory scrutiny, outsourcing to specialists like Birka BioStorage offers a strategic solution. By ensuring the integrity of stored materials, companies can safeguard their projects, maintain compliance, and stay focused on their primary mission: developing life-saving drugs.
